Correction: Wnt5a drives an invasive phenotype in human glioblastoma stem-like cells(Cancer Res (2017) 77 (996-1007) DOI: 10.1158/0008-5472.CAN-16-1693);Wnt5a drives an invasive phenotype in human glioblastoma stem-like cells

Cancer Research

Volumn 77, Issue 4, 2017, Pages 996-1007

  Binda, Elena ^a   Visioli, Alberto ^b   Giani, Fabrizio ^c   Trivieri, Nadia ^a   Palumbo, Orazio ^a   Restelli, Silvia ^b   Dezi, Fabio ^a   Mazza, Tommaso ^a   Fusilli, Caterina ^a   Legnani, Federico ^d   Carella, Massimo ^a   Di Meco, Francesco ^d,e   Duggal, Rohit ^f   Vescovi, Angelo L ^a,b,c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b StemGen SpA   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f SORRENTO THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WNT5A PROTEIN; WNT5A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYME CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR INVASION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STEM CELL; GLIOBLASTOMA; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PHENOTYPE; WNT-5A PROTEIN;

EID: 85014118096     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-1673     Document Type: Erratum

References (50)

1. Delgado-Lopez PD, Corrales-García EM. Survival in glioblastoma: A review on the impact of treatment modalities. Clin Transl Oncol 2016; 18:1062-71.
2. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-6.
3. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007;64:458-78.
4. Giese A, Bjerkvig R, Berens ME, WestphalM. Cost ofmigration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21:1624-36.
5. Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW. Mechanisms regulating glioma invasion. Cancer Lett 2015;362:1-7.
6. Mentlein R, Hattermann K, Held-Feindt J. Lost in disruption: role of proteases in glioma invasion and progression. Biochim Biophys Acta 2012;1825:178-85.
7. Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, et al. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000; 19:4210-20.
8. Kahlert UD, Maciaczyk D, Doostkam S, Orr BA, Simons B, Bogiel T, et al. Activation of canonical WNT/b-catenin signaling enhancesin vitromotility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett 2012;325:42-53.
9. Smalley MJ, Dale TC. Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 1999;18:215-30.
10. Saran A. Medulloblastoma: role of developmental pathways, DNA repair signaling, and other players. Curr Mol Med 2009;9:1046-57.
11. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R. Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neuro Oncol 2008;10:1040-60.
12. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
13. Gong A, Huang S. FoxM1 and Wnt/b-catenin signaling in glioma stem cells. Cancer Res 2012;72:5658-62.
14. Wang K, Xie D, Xie J, Wan Y,Ma L, Qi X, et al. MiR-27a regulates Wnt/betacatenin signaling through targeting SFRP1 in glioma. Neuroreport 2015;26:695-702.
15. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 2003;5:367-77.
16. Sato A, Yamamoto H, Sakane H, Koyama H, Kikuchi A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J 2010; 29:41-54.
17. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
18. Fernandez-Cobo M, Zammarchi F, Mandeli J, Holland JF, Pogo BG. Expression of Wnt5A and Wnt10B in non-immortalized breast cancer cells. Oncol Rep 2007;17:903-7.
19. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006;66:10439-48.
20. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007;26:6560-5.
21. Ripka S, Konig A, Buchholz M, Wagner M, Sipos B, Kloppel G, et al. WNT5A-target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 2007;28:1178-87.
22. Da Forno PD, Pringle JH, Hutchinson P,Osborn J, Huang Q, Potter L, et al. WNT5A expression increases duringmelanoma progression and correlates with outcome. Clin Cancer Res 2008;14:5825-32.
23. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009;16:351-61.
24. Yu JM, Jun ES, Jung JS, Suh SY, Han JY, Kim JY, et al. Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett 2007;257:172-81.
25. Habu M, Koyama H, Kishida M, Kamino M, Iijima M, Fuchigami T, et al. Ryk is essential for Wnt-5a-dependent invasiveness in human glioma. J Biochem 2014;156:29-38.
26. Kamino M, Kishida M, Kibe T, Ikoma K, Iijima M, Hirano H, et al. Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and MMP-2. Cancer Sci 2011;102:540-8.
27. Lee Y, Lee JK, Ahn SH, Lee J, Nam DH. WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest 2016;96:137-50.
28. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21.
29. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev 2015;29:1203-17.
30. Dirks PB. Brain tumor stem cells: The cancer stem cell hypothesis writ large. Mol Oncol 2010;4:420-30.
31. Gritti A, Parati EA, Cova L, Frolichsthal P, Galli R, Wanke E, et al. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J Neurosci 1996;16:1091-100.
32. Vescovi AL, Parati EA,Gritti A, Poulin P, Ferrario M, Wanke E, et al. Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol 1999;156:71-83.
33. Binda E, Visioli A, Giani F, LamorteG, Copetti M, Pitter KL, et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 2012;22:765-80.
34. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
35. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005;7:R444-54.
36. Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. Oxford; New York: Oxford University Press; 2003.
37. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016;131:803-20.
38. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
39. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-25.
40. Brown DV, Daniel PM, D'Abaco GM, Gogos A, Ng W, Morokoff AP, et al. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget 2015;6: 6267-80.
41. Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome. Exp Cell Res 2013;319:2230-43.
42. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010;17:362-75.
43. Balbous A, CortesU, Guilloteau K, Villalva C, Flamant S, Gaillard A, et al. A mesenchymal glioma stem cell profile is related to clinical outcome. Oncogenesis 2014;3:e91.
44. Parish CL, Castelo-Branco G, Rawal N, Tonnesen J, Sorensen AT, Salto C, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. JClin Invest 2008;118:149-60.
45. Kathagen-Buhmann A, Schulte A, Weller J, Holz M, Herold-Mende C, Glass R, et al. Glycolysis and the pentose phosphate pathway are differentially associatedwith the dichotomous regulation of glioblastoma cell migration versus proliferation. Neuro Oncol 2016;18:1219-29.
46. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-5.
47. Jenei V, Sherwood V,Howlin J, Linnskog R, Safholm A, Axelsson L, et al. A tbutyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A 2009;106:19473-8.
48. Vassallo I, Zinn P, Lai M, Rajakannu P, Hamou MF, Hegi ME. WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene 2016;35:12-21.
49. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
50. Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nat Rev Neurosci 2014;15:455-65.